Company intelligence / Profile preview

Xsome

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Xsome Biotech has developed the ResEV platform for precise drug delivery to the lung parenchyma via inhalation, showing several-fold enhancement over liposomes. The company pioneers the use of engineered extracellular vesicles (EVs) for lung regeneration. Its lead program, XO101, is a lung stem cell-based secretome/exosome therapy in preclinical development targeting respiratory diseases

Therapeutic areas: Pulmonology
Modalities: Exosome-based therapyDrug delivery carrier (likely includes Small molecule and/or Protein, but primary focus is exosome-based)
Industry: Biotech

Beyond the preview

Go deeper on Xsome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xsome.

Explore the full profile